These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 2235187)

  • 21. Immunogenicity of Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine in patients who acquired Haemophilus disease despite previous vaccination with type b polysaccharide vaccine.
    Granoff DM; Chacko A; Lottenbach KR; Sheetz KE
    J Pediatr; 1989 Jun; 114(6):925-33. PubMed ID: 2786062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoglobulin deficiency and idiotype expression in children developing Haemophilus influenzae type b disease after vaccination with conjugate vaccine. The Collaborative Study Group.
    Holmes SJ; Lucas AH; Osterholm MT; Froeschle JE; Granoff DM
    JAMA; 1991 Oct; 266(14):1960-5. PubMed ID: 1895474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group.
    Black SB; Shinefield HR
    Pediatr Infect Dis J; 1992 Aug; 11(8):610-3. PubMed ID: 1523069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. National Advisory Committee on Immunization (NACI). Statement on Haemophilus influenzae type B conjugate vaccines for use in infants and children.
    Can Commun Dis Rep; 1992 Dec; 18(23):169-76. PubMed ID: 1291012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of age.
    Berkowitz CD; Ward JI; Chiu CE; Marcy SM; Gordon L; Hendley JO; Meier K; Marchant CD; McVerry P
    Pediatrics; 1990 Mar; 85(3):288-93. PubMed ID: 2304781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: evidence of decreased immunogenicity.
    Adderson EE; Chisholm N; Halperin SA
    Clin Invest Med; 1991 Aug; 14(4):338-45. PubMed ID: 1782732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro induction of IgG1 and IgG2 secretion by B cells of children who developed invasive haemophilus disease despite vaccination.
    Chacko A; Granoff DM
    Pediatr Res; 1991 Jul; 30(1):124-9. PubMed ID: 1891277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population.
    Santosham M; Hill J; Wolff M; Reid R; Lukacs L; Ahonkhai V
    Pediatr Infect Dis J; 1991 Feb; 10(2):113-7. PubMed ID: 2062601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.
    Peltola H; Käyhty H; Sivonen A; Mäkelä H
    Pediatrics; 1977 Nov; 60(5):730-7. PubMed ID: 335348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-dependent V region expression in the human antibody response to the Haemophilus influenzae type b polysaccharide.
    Lucas AH; Azmi FH; Mink CM; Granoff DM
    J Immunol; 1993 Mar; 150(5):2056-61. PubMed ID: 8436834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine (PedvaxHIB) in Papua New Guinean children.
    Lehmann D; Kakazo M; Yarsley S; Javati A; Taime J; Saleu G; Namuigi P; Alpers MP; Mendelman PM; Staub T
    P N G Med J; 1998; 41(3-4):102-11. PubMed ID: 10934551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New considerations for Haemophilus influenzae type b vaccination.
    Pinson JB; Weart CW
    Clin Pharm; 1992 Apr; 11(4):332-6. PubMed ID: 1563228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in 2- to 6-month-old infants.
    Lenoir AA; Granoff PD; Granoff DM
    Pediatrics; 1987 Aug; 80(2):283-7. PubMed ID: 3112729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Anderson EL; Osterholm MT; Holmes SJ; McHugh JE; Belshe RB; Medley F; Murphy TV
    J Pediatr; 1992 Aug; 121(2):187-94. PubMed ID: 1640282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration.
    Fernandez J; Levine OS; Sanchez J; Balter S; LaClaire L; Feris J; Romero-Steiner S
    J Infect Dis; 2000 Nov; 182(5):1553-6. PubMed ID: 11023481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continued shortage of Haemophilus influenzae Type b (Hib) conjugate vaccines and potential implications for Hib surveillance--United States, 2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Nov; 57(46):1252-5. PubMed ID: 19023262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with Haemophilus influenzae type b conjugate vaccines.
    Mäkelä PH; Eskola J; Peltola H; Takala AK; Käyhty H
    Pediatrics; 1990 Apr; 85(4 Pt 2):651-3. PubMed ID: 2179855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine.
    Munoz A; Salvador A; Brodsky NL; Arbeter AM; Porat R
    Pediatrics; 1995 Aug; 96(2 Pt 1):216-9. PubMed ID: 7630672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.